---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-035971"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:21:14.556036+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protara reports 68% six-month CR rate in TARA-002 trial; triggers warrant exercise period

## Summary
- Six-month complete response (CR) rate of 68.0% in 25 BCG-unresponsive NMIBC patients in Phase 2 ADVANCED-2 trial.
- CR rate is consistent with the 68.2% announced on February 24, 2026, and meaningfully above 41.9% threshold.
- Condition met for fixing termination date of April 2024 common stock warrants; exercisable at $5.25 through June 29, 2026.
- Results from open-label trial; further updates may be required for regulatory discussions.

## SEC filing metadata
- accession: 0001213900-26-035971
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390026035971/0001213900-26-035971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390026035971/ea0283949-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-035971
- JSON: https://secwatch.observer/filing/0001213900-26-035971.json
- Plain text: https://secwatch.observer/filing/0001213900-26-035971.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.